FRAMINGHAM, MA -- (MARKET WIRE) -- October 31, 2006 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today provided a review of recent independent scientific publications focused on the possible use of molecular iodine, the active agent in Symbollon’s drug, IoGen™, to treat breast cancer. The results of such research identify molecular iodine as a possible treatment for breast cancer. This research recommends the initiation of human clinical trials testing molecular iodine as an adjuvant therapy for breast cancer.
